NYSE$BDX
Becton Dickinson & Co. · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported strong growth across its base business through continued focused execution and progress against its BD2025 strategy.
BD (Becton, Dickinson and Company) announced results for its second quarter of fiscal year 2022. Revenue of $5.0 billion increased 2.1% as reported and 3.9% on a currency-neutral basis. GAAP diluted EPS was $1.50 and adjusted diluted EPS was $3.18. The company raised the mid-point of its full-year revenue and adjusted EPS guidance ranges, adjusting for the completed spin of Diabetes Care business.
- Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis
- Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year
- GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18
- Company raises mid-point of revenue and adjusted EPS guidance ranges; Adjusts for completed spin of Diabetes Care business
Headline financials
Revenue & EPS history
BD · Revenue · Quarterly
$5.01B
Revenue by segment
BD · $2.53B total across 2 segments · Q4 2023
- BD Life Sciences$1.33B+3.3%52.5%
- BD Interventional$1.2B+9.7%47.5%
Forward guidance
The company raised the mid-point of its full-year revenue and adjusted EPS guidance ranges, and adjusted for the completed spin of Embecta Corp. On a post-spin basis the company expects fiscal year 2022 revenues to be in the range of approximately $18.5 billion to $18.7 billion and adjusted diluted EPS to be $11.15 to $11.30.
Tailwinds
- Revenue guidance for fiscal year 2022 assumes base business currency-neutral revenue growth of 7.25% to 8.25%.
- Growth was also aided by the recent acquisition of Venclose.
- UCC performance was primarily driven by continued strong demand for chronic female incontinence products in the acute care & alternative care settings.
- PI performance reflects growth in the U.S. across the peripheral vascular disease, end stage kidney disease and oncology platforms and double-digit growth in China across the portfolio.
- Surgery performance reflects growth across the hernia, biosurgery and infection prevention platforms as deferrable procedure volumes recovered compared to the prior year.
Headwinds
- Revenue guidance for fiscal year 2022 now assumes approximately $450 million in COVID-19-only diagnostic testing revenues.
- Foreign exchange would represent a headwind of approximately 200 basis points to total company revenue growth.
- Management’s outlook assumes continued inflationary and supply chain pressure over the balance of the fiscal year.
- There should be no further significant escalation of macro-economic headwinds.
- Management’s outlook assumes no significant or lasting disruptions to deferrable procedure volumes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.5%
Avg return
30 days after
38%
28 / 73 earnings
Positive
+8.9%
Q3 2025
Best reaction
-18.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -0.7% | -1.1% | +4.6% | |
| Q1 2026 | -1.3% | +6.5% | -1.2% | |
| Q4 2025 | +0.6% | +7.2% | +10.0% | |
| Q3 2025 | +8.9% | +13.1% | +11.6% | |
| Q2 2025 | -18.1% | -20.3% | -16.7% | |
| Q1 2025 | -6.3% | -5.3% | -5.3% | |
| Q4 2024 | -3.5% | -3.7% | -8.3% | |
| Q3 2024 | +0.3% | -2.3% | +0.6% | |
| Q2 2024 | +0.4% | +1.5% | -0.7% | |
| Q1 2024 | -0.7% | -0.1% | -1.5% | |
| Q4 2023 | -8.3% | -8.8% | -9.2% | |
| Q3 2023 | -2.0% | +1.8% | +0.8% | |
| Q2 2023 | -3.8% | -5.3% | -4.5% | |
| Q1 2023 | -3.3% | -0.4% | -6.7% | |
| Q4 2022 | +4.3% | +1.9% | +13.4% | |
| Q3 2022 | +3.8% | +4.2% | +3.2% | |
| Q2 2022 | +1.7% | -1.4% | -0.5% | |
| Q1 2022 | +4.7% | +7.7% | +7.3% | |
| Q4 2021 | -1.3% | -1.4% | -1.2% | |
| Q3 2021 | -5.4% | -6.3% | +1.2% | |
| Q2 2021 | -4.2% | -3.4% | -3.6% | |
| Q1 2021 | -2.4% | -2.6% | -5.5% | |
| Q4 2020 | -0.1% | +1.5% | +2.5% | |
| Q3 2020 | -9.5% | -10.0% | -17.4% | |
| Q2 2020 | -1.8% | +1.1% | -6.6% | |
| Q1 2020 | -13.7% | -10.3% | -16.4% | |
| Q4 2019 | -3.8% | -6.1% | -0.7% | |
| Q3 2019 | +3.5% | +7.6% | +9.4% | |
| Q2 2019 | -3.0% | -4.1% | +2.6% | |
| Q1 2019 | -1.7% | -2.0% | -0.2% | |
| Q4 2018 | -0.2% | +2.5% | +1.6% | |
| Q3 2018 | -1.1% | -0.8% | +4.7% | |
| Q2 2018 | -2.4% | -3.8% | -2.3% | |
| Q1 2018 | -1.3% | -3.4% | -0.6% | |
| Q4 2017 | +7.9% | +6.3% | +8.8% | |
| Q3 2017 | -1.9% | -2.1% | -0.9% | |
| Q2 2017 | -1.4% | -0.5% | +3.5% | |
| Q1 2017 | +0.2% | -0.1% | +3.2% | |
| Q4 2016 | +4.9% | +7.1% | -0.8% | |
| Q3 2016 | -1.2% | -0.9% | +0.9% | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -2.8% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +4.1% | — | — | |
| Q1 2013 | +3.2% | — | — | |
| Q4 2012 | -4.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | -4.6% | — | — | |
| Q1 2012 | +1.2% | — | — | |
| Q3 2011 | -2.6% | — | — | |
| Q2 2011 | -1.0% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | +0.5% | — | — | |
| Q1 2010 | -1.4% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q2 2009 | -1.2% | — | — | |
| Q4 2009 | -1.2% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q4 2008 | +2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro